Synthesis and structure--activity relationships of N²-alkylated quaternary β-carbolines as novel antitumor agents. 2013

Guoxian Zhang, and Rihui Cao, and Liang Guo, and Qin Ma, and Wenxi Fan, and Xuemei Chen, and Jianru Li, and Guang Shao, and Liqin Qiu, and Zhenghua Ren
School of Chemistry and Chemical Engineering, Sun Yat-sen University, 135 Xin Gang West Road, Guangzhou 510275, PR China.

A series of novel N(2)-alkylated quaternary β-carbolines was synthesized by modification of position-1, 2, 7 and 9 of β-carboline nucleus with various alkyl and arylated alkyl substituents, and their cytotoxic activities in vitro and antitumor potencies in mice were evaluated. Compound 3m was found to be the most potent antitumor agent. SARs analysis revealed that (1) the substituents in position-2 and 9 of β-carboline nucleus played a vital role in modulation of antitumor activity; (2) the benzyl and 3-phenylpropyl substituents in position-2 and 9 of β-carboline ring were the optimal substituents giving rise to significant antitumor agent. These compounds might be a novel promising class of antitumor agents with clinical development potential.

UI MeSH Term Description Entries
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D007928 Lethal Dose 50 The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population. LD50,Dose 50, Lethal
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D002243 Carbolines A group of pyrido-indole compounds. Included are any points of fusion of pyridine with the five-membered ring of indole and any derivatives of these compounds. These are similar to CARBAZOLES which are benzo-indoles. Carboline,Pyrido(4,3-b)Indole,Beta-Carbolines,Pyrido(4,3-b)Indoles,Beta Carbolines
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Guoxian Zhang, and Rihui Cao, and Liang Guo, and Qin Ma, and Wenxi Fan, and Xuemei Chen, and Jianru Li, and Guang Shao, and Liqin Qiu, and Zhenghua Ren
December 2002, Archives of pharmacal research,
Guoxian Zhang, and Rihui Cao, and Liang Guo, and Qin Ma, and Wenxi Fan, and Xuemei Chen, and Jianru Li, and Guang Shao, and Liqin Qiu, and Zhenghua Ren
September 2009, Bioorganic & medicinal chemistry,
Guoxian Zhang, and Rihui Cao, and Liang Guo, and Qin Ma, and Wenxi Fan, and Xuemei Chen, and Jianru Li, and Guang Shao, and Liqin Qiu, and Zhenghua Ren
January 2010, Bioorganic & medicinal chemistry,
Guoxian Zhang, and Rihui Cao, and Liang Guo, and Qin Ma, and Wenxi Fan, and Xuemei Chen, and Jianru Li, and Guang Shao, and Liqin Qiu, and Zhenghua Ren
October 2014, European journal of medicinal chemistry,
Guoxian Zhang, and Rihui Cao, and Liang Guo, and Qin Ma, and Wenxi Fan, and Xuemei Chen, and Jianru Li, and Guang Shao, and Liqin Qiu, and Zhenghua Ren
March 2001, Journal of medicinal chemistry,
Guoxian Zhang, and Rihui Cao, and Liang Guo, and Qin Ma, and Wenxi Fan, and Xuemei Chen, and Jianru Li, and Guang Shao, and Liqin Qiu, and Zhenghua Ren
November 2013, European journal of medicinal chemistry,
Guoxian Zhang, and Rihui Cao, and Liang Guo, and Qin Ma, and Wenxi Fan, and Xuemei Chen, and Jianru Li, and Guang Shao, and Liqin Qiu, and Zhenghua Ren
September 2015, Journal of medicinal chemistry,
Guoxian Zhang, and Rihui Cao, and Liang Guo, and Qin Ma, and Wenxi Fan, and Xuemei Chen, and Jianru Li, and Guang Shao, and Liqin Qiu, and Zhenghua Ren
August 2014, European journal of medicinal chemistry,
Guoxian Zhang, and Rihui Cao, and Liang Guo, and Qin Ma, and Wenxi Fan, and Xuemei Chen, and Jianru Li, and Guang Shao, and Liqin Qiu, and Zhenghua Ren
January 2019, European journal of medicinal chemistry,
Guoxian Zhang, and Rihui Cao, and Liang Guo, and Qin Ma, and Wenxi Fan, and Xuemei Chen, and Jianru Li, and Guang Shao, and Liqin Qiu, and Zhenghua Ren
August 2019, Molecules (Basel, Switzerland),
Copied contents to your clipboard!